Търсене на изпитвания

Намерени 4,436 изпитвания Стр. 130 от 222

Набира участници

Semmelweis Esophageal Cancer Study: Noninvasive Prognostic Parameters in Patients With Oesophageal and Esophagogastric Junction Cancer

Esophageal Cancer (EsC)

The objective of this observational study was to gain a deeper understanding of the epidemiology of the disease in Hungary through a broad analysis of patients with new-onset esophageal-oesophageal-stomach junction tumors, and to identify key parameters that could potentially influence the outcome of the disease and are closely correlated with morbidity and mortality. The investigators' primary objective is to identify potential factors and conditions that could be influenced and modified to enhance the disease outcome. Main questions: 1. What are the measurable changes in performance, workload, nutritional status, cardiac function, mental status in the patients studied? 2. What is the time course of the changes during and after treatment? 3. Which pathological parameters are associated with disease outcome and which are potential points of intervention to improve the course of the disease? Patients will undergo a detailed physical and nutritional assessment, non-invasive imaging tests and several questionnaires in addition to the usual pre- and post-operative examinations.

Начало: 10.09.2024 Край: 10.09.2034 Възраст: от 18 г.

Hungary Semmelweis University NCT06713993

Набира участници Фаза 3

PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.

Androgen Axis Suppression Prostatectomy Prostate Cancer

1. Personalize treatment for prostate cancer based on how aggressive the disease is and 2. Learn if apalutamide-based treatment can help to reduce fatigue and other side effects of treatment in participants who are being treated with radiation therapy for prostate cancer, as compared to standard therapy.

Начало: 10.09.2024 Край: 30.06.2029 Възраст: от 18 г.

United States M.D. Anderson Cancer Center NCT06274047

Набира участници

Natural History of Depression, Bipolar Disorder and Suicide Risk

Behavioral Symptoms Suicide Self-Injurious Behavior Sensory System Agents +17

Mood disorders, such as depression and bipolar disorder, are difficult to treat. One reason is that there are no objective ways to measure how these disorders affect the body and respond to different treatments. In this study, researchers want to perform tests on people undergoing clinical care for mood disorders. The purpose is to understand the experience of receiving treatment for depression, bipolar disorder, and suicide risk. We also hope that this study will help us to predict which medications will improve thoughts of suicide. People 18 years or older who are receiving treatment for depression, bipolar disorder, or suicide risk may take part in this study. Participants must have also been enrolled in protocol 01-M-0254. This study will be conducted at the NIH Clinical Center in Bethesda, MD. The study typically lasts up to 12 weeks, but may last longer if a participant s treatment continues past that time. Participants will have weekly interviews and questionnaires while they are being treated for their mood disorder. Other tests are optional and include psychological testing, blood draws, sleep tests, and imaging scans. These will be done at the start and the end of research participation....

Начало: 09.09.2024 Край: 01.06.2030 Възраст: 18–120 г.

United States National Institute of Mental Health (NIMH) NCT06462196

Набира участници Фаза 2

Pinoxin for the Prevention of Radiation-Induced Skin Injury

Cancer Patients Undergoning Radiotherapy

The incidence of radiation-induced skin injury is high, and effective preventive measures are currently lacking. This study evaluates the role of the skin protective agent Pinoxin in preventing skin injury. Patients are randomly assigned into two prospective groups: treatment group and control group. In treatment group, patients will receive Pinoxin treatment. In control group，patients will receive placebo treatment. The rate of grade 2 or greater skin injury will be analyzed.

Начало: 05.09.2024 Край: 31.12.2026 Възраст: от 18 г.

China Fudan University NCT07545720

Набира участници

Prospective Study Evaluating the Treatment Outcomes for Localised Recurrent, Resectable Retroperitoneal Liposarcoma

Retroperitoneal Liposarcoma

The aim of the study is to collect prospective data on the treatment outcomes in patients with first localized, resectable recurrent retroperitoneal well-differentiated and/or dedifferentiated liposarcoma undergoing curative intent treatment. Patients enrolled in this study will form a validation cohort of the TARPSWG recurrent RPS nomogram. The treatment decision (surgery alone, or preoperative RT +/- chemotherapy followed by surgery) is per the institutional multidisciplinary team recommendation.

Начало: 05.09.2024 Край: 01.12.2032 Възраст: от 18 г.

Australia, Belgium, Brazil +2 Australia and New Zealand Sarcoma Association NCT07377747

Набира участници

Study of Axial and Cognitive Symptoms and Biomarkers of Neurodegeneration in Brain-first and Body-first PD

Parkinson Disease Parkinsonian Disorders Brain Disease Basal Ganglia Diseases +1

This observational study aims to systematically characterize a cohort of patients with early-stage Parkinson's disease (PD) attending the Movement Disorders Center of AUSL-IRCCS Reggio Emilia, Italy. PD is the second most common neurodegenerative disorder, affecting about 1% of individuals over 60 years of age. The project will explore clinical and biological differences between the recently proposed "Brain-First" and "Body-First" phenotypes of PD. Patients will undergo detailed clinical evaluation, neuroimaging, and biomarker assessments (including neurodegeneration and neuroinflammation markers). Particular attention will be given to the progression of axial and cognitive symptoms, which represent major contributors to disability. Findings from this study are expected to improve early patient stratification, clarify disease mechanisms, and support the development of precision medicine strategies and future disease-modifying therapies.

Начало: 04.09.2024 Край: 01.05.2031 Възраст: от 18 г.

Italy Azienda USL Reggio Emilia - IRCCS NCT07187843

Набира участници Фаза 3

The Chronic Kidney Disease Adaptive Platform Trial Investigating Various Agents for Therapeutic Effect

Chronic Kidney Diseases

CAPTIVATE is an international, multi-centre, Phase III, adaptive, platform, randomised controlled trial in people with chronic kidney disease (CKD). CAPTIVATE aims to find the best treatment, or combination of treatments, that slow the progression of CKD so that fewer people develop kidney failure. CAPTIVATE provides a research platform that allows many treatment-related questions to be answered within a common trial set-up.

Начало: 04.09.2024 Край: 31.03.2029 Възраст: от 18 г. Лечение

Australia, India, New Zealand +2 The George Institute NCT06058585

Набира участници Фаза 2

A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)

Lupus Erythematosus, Systemic Lupus Nephritis

The purpose of this study is to evaluate the efficacy and safety of rapcabtagene autoleucel (administered once following lymphodepletion) in patients with active, refractory systemic lupus erythematosus (SLE) or active, refractory lupus nephritis (LN).

Начало: 04.09.2024 Край: 06.02.2032 Възраст: 18–75 г. Лечение

Australia, Brazil, Czechia +17 Novartis Pharmaceuticals NCT06581198

Набира участници Фаза 3

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NASH - Nonalcoholic Steatohepatitis MASH - Metabolic Dysfunction-Associated Steatohepatitis

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

Начало: 04.09.2024 Край: 01.03.2030 Възраст: 18–80 г. Лечение

Argentina, Australia, Brazil +16 Akero Therapeutics, Inc NCT06528314

Набира участници Фаза 2

A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)

Pulmonary Hypertension Heart Failure With Preserved Ejection Fraction

TX000045-003 is a double-blind, randomized, parallel group, placebo-controlled, proof- of-concept (POC) study, evaluating 2 dose regimens of TX000045 over the course of a 24-week treatment period (the APEX study).

Начало: 04.09.2024 Край: 20.11.2026 Възраст: 18–83 г. Лечение

Armenia, Australia, Belgium +12 Tectonic Therapeutic NCT06616974

Набира участници Фаза 1/2

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

Solid Tumor, Adult

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors

Начало: 03.09.2024 Край: 01.02.2027 Възраст: от 18 г. Лечение

Australia, China, United States DualityBio Inc. NCT06554795

Набира участници

IMARA for Black Male Caregivers and Girls Empowerment (IMAGE)

Sexually Transmitted Infections (Not HIV or Hepatitis) HIV Infections Sexual Behavior

The scientific premise of this research is that individual, interpersonal, and structural factors impact Black girls' sexual reproductive health outcomes (sexually transmitted infection (STI) and Human Immunodeficiency Virus (HIV)) and experience of sexual violence. This study expands STI/HIV prevention programs to include Black male caregivers, a potentially valuable yet underutilized resource to protect Black girls and reduce their exposure to STI/HIV and sexual violence.

Начало: 02.09.2024 Край: 31.05.2028 Възраст: от 13 г.

United States University of Illinois at Chicago NCT06266416

Набира участници

Frequency of Selected Single Nucleotide Polymorphisms in Huntington Disease Gene Expansion Carriers

Huntington Disease

For participation in this epidemiological study, a single-day visit at the study site is required. Participants will be recruited from Huntington Disease clinics, and they will be asked to answer questions regarding their demographics, including sex, age, race and ethnicity, and their medical and medication history. At the end of the visit, a blood sample will be drawn to allow testing with a sequencing assay that is specifically designed for phasing single nucleotide polymorphisms (SNPs) on the wild-type Huntington (wtHTT) and mutant Huntington (mHTT) alleles.

Начало: 02.09.2024 Край: 24.09.2028 Възраст: 25–60 г.

Argentina, Australia, Canada +7 Hoffmann-La Roche NCT06667414

Набира участници

Respiratory Sinus Arrhythmia Pacing Post-CABG Surgery in Patients With HFrEF

Heart Failure With Reduced Ejection Fraction

The goal of this clinical trial is to test a new type of pacemaker in heart failure patients following a heart bypass operation. The new pacemaker restores respiratory sinus arrhythmia which is a natural pattern where the heart rate increases when the participants breathe in and slows down when participants breathe out. The main questions the trial aims to answer are: * Is the new type of pacemaker safe? * Does the new type of pacemaker improve how patients' hearts work (also known as cardiac output)? Participants will have a range of tests before their operation and during their recovery in hospital while participants have the new type of pacemaker in place, and will be monitored very closely. Participants will also receive a phone call 1 month after their surgery. Researchers will compare the new type of heart pacing against standard treatment to see if it is as safe, and if it is any better for patients.

Начало: 02.09.2024 Край: 01.04.2026 Възраст: от 22 г. Лечение

Australia, New Zealand Ceryx Medical Australia NCT06384963

Набира участници

Arlington Aging Study

Aging

The goal of this observational study is to learn about the mechanisms causing functional decline with age, using magnetic resonance imaging, exercise science, integrative physiology, neuroscience, and remote monitoring. Specific aims include: Aim 1: Advance knowledge of the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability. Aim 2: Determine the effects of personal and societal factors on aging. Aim 3: Examine the influence of racial/ethnic and sex differences on the biology of aging and its impact on the prevention, progression, and prognosis of disease and disability.

Начало: 01.09.2024 Край: 31.12.2030 Възраст: 18–85 г.

United States The University of Texas at Arlington NCT06857877

Набира участници

Optimizing Care in Critically Ill at UCHealth by Liberalizing the Target O2 in Mechanically-ventilated ICU Patients

Respiratory Failure Acute Hypoxemic Respiratory Failure Acute Hypoxic Respiratory Failure Hypoxemia +2

A multimodal educational intervention to target an oxygen saturation target range (SpO2 90-96%) will reduce ventilator length of stay and reduce occult hypoxemia by increased awareness and adherence to a designated oxygen saturation target range.

Начало: 01.09.2024 Край: 31.07.2026 Възраст: от 18 г.

United States University of Colorado, Denver NCT06501118

Набира участници

Methotrexate Combined With Tofacitinib in Rheumatoid Arthritis

Rheumatoid Arthritis

Rheumatoid arthritis (RA) is the leading cause of disability in Chinese women. We established a synovial pathology queue in the early stage and proposed a new synovial immunopathology classification. We found that baseline myeloid stromal RA patients had severe conditions and poor outcome. Early identification of synovial myeloid stromal RA patients and intensified treatment are key to improving RA efficacy. This project aims to conduct a randomized, controlled, open label, multicenter clinical study on early intensified treatment of RA based on synovial pathology classification. 130 adult patients with synovial myeloid stromal type of primary treatment moderate to severe active RA were planned to be enrolled in three centers: Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University; Shenshan Medical Center, Memorial Hospital of Sun Yat-Sen University, and Guangzhou Panyu Central Hospital. They were randomly divided into an intensive treatment group and a conventional treatment group in a 1:1 ratio. The intensive treatment group was treated with methotrexate combined with tofacitinib, while the conventional treatment group was treated with methotrexate monotherapy. The expected intervention period is 12 weeks, with a follow-up period of 48 weeks. The primary endpoint is the proportion of subjects who achieved ACR20 at week 12. Secondary endpoint indicators include improvement in disease activity and joint function among subjects at different follow-up points, safety, and the proportion of subjects who experienced joint destruction progression at week 48. This project proposes the concept of achieving precise diagnosis of RA based on synovial pathology classification, and explores the efficacy of early methotrexate combined with tofacitinib intensified treatment for patients with synovial medullary stromal RA who have poor conventional treatment efficacy, providing high-level clinical evidence for achieving precise initial treatment of RA treatment guidelines.

Начало: 01.09.2024 Край: 01.04.2030 Възраст: 18–65 г.

China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NCT06301373

Набира участници

Pharmacist-led Continuous Glucose Monitoring

Type 2 Diabetes

This is a pilot study. The goal of this prospective cohort study is to determine impact of pharmacist-led continuous glucose monitoring on glycemic control and health behavior change in people with type 2 diabetes. The main questions it aims to answer are: 1. to assess change in hemoglobin A1c in people with type 2 diabetes using continuous glucose monitoring under a pharmacist-led approach as compared to a pharmacist-led approach utilizing no continuous glucose monitoring (only self-monitoring blood glucose with a glucometer). 2. to assess change in continuous glucose monitoring-derived glycemic outcomes among the pharmacist-led continuous glucose monitoring cohort (intervention group) 3. to assess change in health behavior among the pharmacist-led continuous glucose monitoring cohort (intervention group)

Начало: 01.09.2024 Край: 30.06.2026 Възраст: от 18 г.

United States University of South Florida NCT06572306

Набира участници

Rural Illinois Lung Cancer Screening Initiative

Lung Cancer

The role of this observational study is to access the feasibility of providing lung cancer screening using a designated nurse navigator through lung cancer screening clinic. Eligible participants will be identified using medical records, eligibility will be confirmed through phone call, screening visits will be scheduled as in-person visit or telehealth visit. Computed tomography screening will be performed at an approved center closer to the individuals place of living and results will be discussed during follow-up in-person visit or telehealth visit.

Начало: 01.09.2024 Край: 31.08.2030 Възраст: 50–80 г.

United States Southern Illinois University NCT06084078

Набира участници Фаза 1

Efficacy and Safety of Autologous Peptide-induced Active Immunity in AML Maintenance Therapy

Acute Myeloid Leukemia Personalized Active Immunotherapy Maintenance Therapy

Acute myeloid leukemia (AML) is the most common acute leukemia in adults. While approximately 70% of patients achieve complete remission (CR) with induction chemotherapy, traditional consolidation therapy (predominantly high-dose cytarabine) has a persistently high recurrence rate - nearly 30% at 1 year for low-risk groups and 80% for high-risk groups - with a long-term survival rate \

Начало: 01.09.2024 Край: 01.09.2026 Възраст: 18–70 г.

China Fujian Medical University Union Hospital NCT07551037

1 … 128 129 130 131 132 … 222